arrow
C

Claudia Cardone

istituto nazionale tumori - irccs - fondazione g. pascale
H指数:25
被引数:2,651

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

ESMO肿瘤不可知分类器和筛选器 (etac-s): 一种评估分子引导疗法的肿瘤不可知潜力和指导药物开发的工具

2024-11-012
OAAI
Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
2024-03-220
PRE
Young oncologists' perspective on the role and future of the clinician-scientist in oncology
2023-10-013
OAAI
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
2023-06-011
OA
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Regorafenib单药治疗RAS突变型晚期结直肠癌 (STREAM) 患者的二线治疗: 一项学术,多中心,单臂,两阶段,II期研究

2023-02-012
OAAI
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (vol 18, 405, 2020)
2021-10-211
OAAI
Skip pattern approach toward the early access of innovative anticancer drugs
2021-08-012
OAAI
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

低剂量联合伊立替康和尼拉帕尼在ATM突变的结直肠癌中的脆弱性

2021-01-0621
OAAI
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
2020-10-2192
OAAI
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

AXL是RAS野生型转移性结直肠癌生存率低和抗EGFR治疗耐药的预测因子

2020-10-0130
PREAI